Patients with T2DM treated with denosumab exhibit lower glycated hemoglobin levels compared with those treated with bisphosphonates or calcium and vitamin D supplementation, highlighting the role of the RANK-RANKL system and implicating DPP-4 as a potential mediator between bone remodeling and energy metabolism [3]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.